CMC Biologics Expands GMP Manufacturing Capacity in the United States and Europe
Company plans to add more than 30,000L of bioreactor capacity across its three sites
11-May-2015
- Denmark
"This global expansion addresses increasing demands from our customers for late-stage and commercial manufacturing," said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. "CMC Biologics is investing in innovative facility design to provide the production flexibility needed to meet aggressive regulatory and production timelines and speed our customers' products to market."
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.